Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc. demonstrates a positive outlook primarily due to increased confidence in the market potential of its pipeline products, particularly AXPAXLI, with peak risk-adjusted sales estimates significantly raised from $1.9 billion to $3.2 billion. The company's wet AMD and NPDR Phase 3 programs have also seen upward revisions in their peak risk-adjusted sales projections, now estimated at $2.1 billion and $1.1 billion, respectively. Furthermore, data from its SOL-X initiative is anticipated to enhance both short-term and long-term patient retention, thereby expanding the market opportunity for the company's innovative therapies.

Bears say

Ocular Therapeutix faces significant challenges due to the negative performance comparisons between its product ranibizumab and competitors, specifically aflibercept, raising concerns about its efficacy and market acceptance. Additionally, the company's acknowledgment of skepticism regarding the market opportunity for anti-VEGF therapies, stemming from the infrequent prescription rates and the difficulties associated with regular injections for working-aged patients, further compounds the potential for limited commercial success. Lastly, various risks, including the potential failure of its clinical trial AXPAXLI and issues related to regulatory approval and market penetration, add to the uncertainty surrounding Ocular Therapeutix's growth prospects.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.